JAKARTA - A number of new investors will become shareholders of PT Diagnos Laboratorium Utama Tbk (DGNS) via a rights issue that will be approved by shareholders next week (2/10).

Quoted from the brief prospectus, Tuesday (24/9), DGNS's authorized capital is recorded at IDR 100 billion, issued and fully paid capital at IDR 31.25 billion, with the owner structure, namely, Bunda Investama Indonesia (BII) 38.80% and PT Bundamedik Tbk (BMHS) 41.20%, and the public 20%. The number of shares in the portfolio is IDR 78.75 billion.

Assuming that public shareholders exercise their rights in the rights issue later, the paid-in and placed capital will be IDR 53.79 billion and the portfolio shares will be IDR 46.20 billion.

The shareholder structure is BMHS 23.93%, BII 26.25%, the public 20.18%, and new investors receiving the transfer, namely, Aloysius Liang Jiahao 5.14%, Mercy Venture Partners Fund II LP 3.29%, Magzhan Kenesbai 2.59%, SBI Kejora Orbit Fund I LP 2.21%, PT Royal Arta Jayamanggala 1.55%, Kelvin Davis Hardjono, and Viko Technologies Pte Ltd, Viko Technologies Pte Ltd, Selina Loh, Sastrawan Kamto, Prundjaya Capital Pte Ltd each 1.5%.

In addition, Illumin8.ai Pte Ltd, 1.48%, Top Harvest Holdings Limited 1.19%, Naya Investor Holdings Limited 1.03%, Top Harvest Fund I(Q)LP 0.87%, PT Cakrawala data Integrasi 0.74%, NSV Maxwell Limited 0.74%, Marcy Venture Partners Culture Fund II LP 0.40%, Shor Administrative Consultancy LLC 0.35%, Orbit Capital (Malaysia) Sdn, Bhd 0.30%, Maxime Franzetti 0.15%, and Stefanus Ade Hadiwidjaja 0.07%.

It is known that in this corporate action plan, the company will take over most of Asa Ren's shares from its shareholders via non-cash capital deposits (inbreng) and the acquisition of Asa Ren shares from its shareholders. The value of the takeover plan is US$24.10 million or equivalent to IDR 357.89 billion. The details are, the inbreng value is IDR 322.10 billion and the purchase of shares is IDR 35.78 billion. (LK/LM)